Structure and haemostatic effects of generic versions of enoxaparin available for clinical use in Brazil: Similarity to the original drug

Thrombosis and Haemostasis

Volumn 107, Issue 2, 2012, Pages 302-314

  Glauser, Bianca F ^a   Vairo, Bruno C ^a   Oliveira, Stephan Nicollas M C G ^a   Cinelli, Leonardo P ^a   Pereira, Mariana S ^a   Mourão, Paulo A S ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Anticoagulants; Antithrombotic agents; Generic drugs; Heparin; Low molecular weight heparins

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; GENERIC DRUG; LOW MOLECULAR WEIGHT HEPARIN; MONOSACCHARIDE; PROTHROMBIN A; TETRASACCHARIDE; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLEEDING; BRAZIL; CHEMICAL COMPOSITION; DRUG FORMULATION; DRUG STRUCTURE; FEMALE; HEMOSTASIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOLECULAR SIZE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RAT; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; BRAZIL; DISEASE MODELS, ANIMAL; DRUGS, GENERIC; ENOXAPARIN; FACTOR XA; FEMALE; HEMORRHAGE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PATENTS AS TOPIC; PROTHROMBIN; RATS; RATS, WISTAR; THERAPEUTIC EQUIVALENCY; THROMBOSIS;

EID: 84856688126     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th11-09-0664     Document Type: Article

References (17)

1. Weitz, JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-698.
2. Bisio A, Vecchietti D, Citterio M, et al. Structural features of low-molecularweight heparins affecting their affinity to antithrombin. Thromb Haemost 2009; 102: 865-873.
3. Fareed J, Leong WL, Hoppensteadt DA, et al. Generic low-molecular-weight heparins: some practical considerations. Semin Thromb Haemost 2004; 30: 703-713.
4. Harenberg J, Kakkar A, Bergqvist D, et al. Recommendations on biosimlar lowmolecular- weight-heparins. J Thromb Haemost 2009; 7: 1222-1225.
5. Jeske WP, Walenga JM, Hoppensteadt DA, et al. Differentiating low-molecularweight heparins based on chemical, biological and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Semin Thromb Haemost 2008; 34: 74-85.
6. Dische Z. A specific color reaction for glucuronic acid. J Biol Chem 1947; 167: 189-198.
7. Aquino RS, Pereira MS, Vairo BC, et al. Heparins from porcine and bovine intestinal mucosa: are they similar drugs? Thromb Haemost 2010; 103: 1005-1015.
8. Komatsu H, Takahata T, Tanaka M, et al. Determination of the molecular-weight distribution of low-molecular-weight heparins using high-performance gel permeation chromatography. Biol Pharm Bull 1993; 16: 1189-1193.
9. Olson ST, Björk I, Shore JD. Kinetic Characterization of Heparin-Catalyzed and Uncatalyzed Inhibition of Blood Coagulation Proteinases by Antithrombin. Methods Enzymol 1993; 222: 525-559.
10. Fonseca RJ, Oliveira SN, Pomin VH, et al. Effects of oversulfated and fucosylated chondroitin sulfates on coagulation. Challenges for the study of anticoagulant polysaccharides. Thromb Haemost 2010; 103: 994-1004.
11. Herbert JM, Bernat A, Maffrand JP. Importance of platelets in experimental venous thrombosis in the rat. Blood 1992; 80: 2281-2286.
12. Guerrini M, Guglieri S, Naggi A, et al. Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy. Semin Thromb Haemost 2007; 33: 478-487.
13. Guerrini M, Guglieri S, Naggi A, et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008; 26: 669-675.
14. Collignon F, Frydman A, Caplain H, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995; 73: 630-640.
15. Gray E, Mulloy B. Biosimilar low molecular weight heparin products. J Thromb Haemost 2009; 7: 1218-1221.
16. Gomes M, Ramacciotti E, Litinas E, et al. Concerns on generic enoxaparin use in acute coronary syndrome. Arq Bras Card 2010; 95: 551-552.
17. Lever R, Page CP. Novel drug development opportunities for heparin. Nature reviews: Drug Discov 2002; 1: 140-148.